BDBM575621 (2R,2′R)-2,2′-((((((2,2′-dimethyl-[1,1′- biphenyl]-3,3′-diyl)bis(azanediyl))bis (carbonyl))bis(4-methoxypyridine-6,3- diyl))bis(methylene))bis(azanediyl)bis(4- hydroxybutanoic acid)::US11459339, Example 71

SMILES COc1cc(ncc1CN[C@H](CCO)C(O)=O)C(=O)Nc1cccc(c1C)-c1cccc(NC(=O)c2cc(OC)c(CN[C@H](CCO)C(O)=O)cn2)c1C

InChI Key InChIKey=TWWSCVJVWZHJDS-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 575621   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575621(US11459339, Example 71 | (2R,2′R)-2,2′...)
Affinity DataIC50: 0.330nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent